No significant benefit of Umifenovir in COVID-19 treatment: Glenmark Pharmaceuticals

Glenmark said that this was the second clinical study after the successful Favipiravir monotherapy trial earlier this year.

published on : 9th October 2020

COVID-19: CSIR institute gets nod for conducting clinical trials of antiviral drug Umifenovir

Umifenovir is mainly used for treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for COVID-19 patients.

published on : 19th June 2020

Glenmark Pharmaceuticals to study efficacy of two antiviral drugs for treating COVID-19

The Glenmark study will examine whether early administration of a combination of Favipiravir and Umifenovir enhances antiviral efficacy.

published on : 26th May 2020